HCB101
Sponsors
FBD Biologics Limited, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital
Conditions
Advanced Solid TumorCRCHNSCCRefractory Non-Hodgkin LymphomaSolid Cancer
Phase 1
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
RecruitingNCT05892718
Start: 2023-10-02End: 2029-11-15Target: 80Updated: 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
Active, not recruitingNCT06771622
Start: 2025-03-13End: 2029-01-01Target: 500Updated: 2026-02-04
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
RecruitingNCT07136545
Start: 2025-08-01End: 2026-12-31Target: 50Updated: 2025-09-10
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
RecruitingNCT07204574
Start: 2025-05-14End: 2025-12-31Target: 40Updated: 2025-10-02